Seyhan Sahan-Firat Selected Research

Controlled Hypotension

1/2022	Activation of GPR75 Signaling Pathway Contributes to the Effect of a 20-HETE Mimetic, 5,14-HEDGE, to Prevent Hypotensive and Tachycardic Responses to Lipopolysaccharide in a Rat Model of Septic Shock.
1/2019	NF-κB activation mediates LPS-or zymosan-induced hypotension and inflammation reversed by BAY61-3606, a selective Syk inhibitor, in rat models of septic and non-septic shock.
5/2017	Activation of mTOR/IκB-α/NF-κB pathway contributes to LPS-induced hypotension and inflammation in rats.
1/2012	A novel treatment strategy for sepsis and septic shock based on the interactions between prostanoids, nitric oxide, and 20-hydroxyeicosatetraenoic acid.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Seyhan Sahan-Firat Research Topics

Disease

16	Hypotension (Low Blood Pressure) 01/2022 - 05/2010
15	Inflammation (Inflammations) 01/2022 - 01/2012
11	Septic Shock (Toxic Shock Syndrome) 01/2022 - 01/2012
5	Tachycardia (Tachyarrhythmias) 01/2022 - 04/2013
5	Shock 12/2019 - 05/2010
5	Endotoxemia 02/2018 - 05/2010
4	Hypertension (High Blood Pressure) 01/2022 - 10/2010
4	Hypertrophy 01/2022 - 10/2010
3	Hyperalgesia 03/2021 - 04/2017
2	Cardiovascular Diseases (Cardiovascular Disease) 01/2022 - 10/2010
2	Pain (Aches) 03/2021 - 01/2021
2	Ischemia 12/2019 - 01/2012
2	Necrosis 01/2019 - 01/2018
2	Sepsis (Septicemia) 05/2017 - 01/2012
2	Multiple Organ Failure (MODS) 01/2012 - 09/2011
1	Arteritis 01/2022
1	B-Cell Lymphoma (Lymphoma, B Cell) 09/2021
1	Neuroinflammatory Diseases 09/2021
1	Hypoxia (Hypoxemia) 09/2021
1	Multiple Sclerosis 12/2020
1	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 12/2020
1	Wounds and Injuries (Trauma) 12/2019
1	Mycoses (Diseases, Fungus) 01/2018
1	Metabolic Diseases (Metabolic Disease) 05/2017
1	Neoplasms (Cancer) 05/2017

Drug/Important Bio-Agent (IBA)

10	LipopolysaccharidesIBA 01/2022 - 01/2012
9	20-hydroxy-5,8,11,14-eicosatetraenoic acidIBA 01/2022 - 05/2010
7	Cytochrome P-450 Enzyme System (Cytochrome P450)IBA 12/2019 - 05/2010
7	Nitric Oxide (Nitrogen Monoxide)FDA Link 12/2019 - 11/2010
7	Vasodilator Agents (Vasodilators)IBA 01/2019 - 05/2010
6	Proteins (Proteins, Gene)FDA Link 01/2021 - 05/2010
6	Nitric Oxide Synthase (NO Synthase)IBA 12/2019 - 05/2010
5	N-(20-hydroxyeicosa-5,14-dienoyl)glycineIBA 01/2022 - 05/2010
5	Prostaglandin-Endoperoxide Synthases (Cyclooxygenase)IBA 12/2019 - 09/2011
5	Nitric Oxide Synthase Type II (Inducible Nitric Oxide Synthase)IBA 02/2018 - 01/2012
4	TOR Serine-Threonine KinasesIBA 01/2022 - 05/2017
4	Glycine (Aminoacetic Acid)FDA LinkGeneric 01/2022 - 01/2012
4	CytokinesIBA 03/2021 - 01/2012
4	EnzymesIBA 01/2018 - 01/2012
4	Peroxynitrous Acid (Peroxynitrite)IBA 05/2017 - 04/2011
3	Desoxycorticosterone (Deoxycorticosterone)IBA 01/2022 - 12/2010
3	Desoxycorticosterone Acetate (DOCA)FDA Link 01/2022 - 12/2010
3	Sirolimus (Rapamycin)FDA Link 01/2022 - 12/2019
3	SaltsIBA 01/2022 - 12/2010
3	InflammasomesIBA 01/2021 - 04/2017
3	Epoxide HydrolasesIBA 01/2021 - 04/2013
3	Vasoconstrictor AgentsIBA 12/2019 - 05/2010
3	Arachidonic Acid (Vitamin F)IBA 12/2019 - 05/2010
3	EndotoxinsIBA 12/2019 - 09/2011
3	EicosanoidsIBA 12/2019 - 01/2012
3	ZymosanIBA 01/2019 - 01/2018
3	ProstaglandinsIBA 07/2013 - 05/2010
3	Reactive Oxygen Species (Oxygen Radicals)IBA 08/2012 - 10/2010
3	Angiotensin IIIBA 08/2012 - 10/2010
3	2,4,3',5'-tetramethoxystilbeneIBA 08/2012 - 10/2010
2	Acetates (Acetic Acid Esters)FDA Link 01/2022 - 12/2010
2	Bexarotene (LGD1069)FDA Link 03/2021 - 02/2018
2	Caspase 1 (ICE Protease)IBA 01/2021 - 04/2017
2	NucleotidesIBA 01/2021 - 04/2017
2	NitrogenIBA 12/2019 - 01/2012
2	Oxygen (Dioxygen)IBA 12/2019 - 01/2012
2	Protein Isoforms (Isoforms)IBA 12/2019 - 04/2017
2	Syk KinaseIBA 01/2019 - 01/2018
2	2- (7- (3,4- dimethoxyphenyl)imidazo(1,2- c)pyrimidin- 5- ylamino)nicotinamideIBA 01/2019 - 01/2018
2	NADP (NADPH)IBA 02/2018 - 04/2017
2	NADPH Oxidases (NAD(P)H oxidase)IBA 02/2018 - 08/2012
2	Peroxidase (Myeloperoxidase)IBA 01/2018 - 05/2017
2	CaspasesIBA 04/2017 - 01/2012
1	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 01/2022
1	bcl-2-Associated X Protein (bcl 2 Associated X Protein)IBA 09/2021
1	Caspase 3 (Caspase-3)IBA 09/2021
1	Neuroprotective AgentsIBA 03/2021
1	14,15-dihydroxyeicosatrienoic acidIBA 01/2021
1	InterleukinsIBA 01/2021
1	Histamine (Histamine Dihydrochloride)FDA Link 12/2019
1	Serotonin (5 Hydroxytryptamine)IBA 12/2019
1	BradykininIBA 12/2019
1	Interleukin-8 (Interleukin 8)IBA 01/2019
1	Phosphotransferases (Kinase)IBA 02/2018
1	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 02/2018
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 02/2018
1	Toll-Like Receptors (Toll-Like Receptor)IBA 01/2018
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2018
1	Ribosomal Protein S6IBA 05/2017
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 05/2017
1	Epoprostenol (Prostacyclin)FDA LinkGeneric 05/2017
1	Protein Serine-Threonine Kinases (Protein-Serine-Threonine Kinase)IBA 05/2017
1	Toll-Like Receptor 4IBA 05/2017
1	3-nitrotyrosineIBA 04/2017
1	Oxidoreductases (Dehydrogenase)IBA 04/2017
1	N- (1,2,3,5,6,7- hexahydro- S- indacen- 4- ylcarbamoyl)- 4- (2- hydroxy- 2- propanyl)- 2- furansulfonamideIBA 04/2017
1	Leucine-Rich Repeat ProteinsIBA 04/2017
1	Transcription Factor AP-1 (Transcription Factor AP 1)IBA 05/2016
1	4- ethoxymethylene- 2- phenyl- 2- oxazoline- 5- one (phOx)IBA 09/2013
1	Superoxides (Superoxide)IBA 09/2013
1	Cyclic GMP-Dependent Protein Kinases (Protein Kinase G)IBA 09/2013
1	Soluble Guanylyl CyclaseIBA 09/2013
1	N- (2- cyclohexyloxy- 4- nitrophenyl)methanesulfonamideIBA 07/2013
1	Dinoprostone (PGE2)FDA Link 07/2013

Therapy/Procedure

4	Controlled Hypotension 01/2022 - 01/2012